Repligen
RGEN
#2598
Rank
NZ$11.60 B
Marketcap
NZ$205.73
Share price
0.27%
Change (1 day)
-4.52%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of December 2025 : NZ$1.18 Billion

According to Repligen 's latest financial reports the company's total debt is NZ$1.18 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2025-12-31NZ$1.19 B-2.1%
2024-12-31NZ$1.21 B8.11%
2023-12-31NZ$1.12 B68.96%
2022-12-31NZ$0.66 B24.31%
2021-12-31NZ$0.53 B40.4%
2020-12-31NZ$0.38 B-2.37%
2019-12-31NZ$0.39 B153.42%
2018-12-31NZ$0.15 B10.4%
2017-12-31NZ$0.13 B1.61%
2016-12-31NZ$0.13 B
2005-03-31NZ$0.16 M31.36%
2004-03-31NZ$0.12 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
NZ$109.56 B 9,170.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
NZ$67.46 B 5,608.40%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
NZ$35.10 B 2,870.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$80.74 B 6,732.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
NZ$43.55 M-96.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
NZ$0.42 B-63.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
NZ$0.71 B-39.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
NZ$0.60 B-49.14%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
NZ$1.03 B-12.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
NZ$4.40 B 272.55%๐Ÿ‡บ๐Ÿ‡ธ USA